Celularity Inc

GX Acquisition Corp II (Nasdaq: GXGX), sponsored by GX Sponsor II LLC, completed its SPAC initial public offering in 2020 targeting the healthcare and biotechnology sector. The vehicle announced a business combination with Celularity Inc., a clinical-stage biopharmaceutical company developing off-the-shelf, placental-derived cell therapies for oncology and infectious disease applications. The 10-Q filing dated May 24, 2021, bearing accession number 0001213900-21-028857, was submitted under the Celularity Inc. registrant name as the transaction progressed toward closing, reflecting the combined entity's transition from blank-check company to operating biotech. The deal represented one of the more prominent cell-therapy de-SPAC transactions of the 2020-2021 wave. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on GXGX and hundreds of other SPACs.